These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 36497490)

  • 21. Cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) versus standard of care (SoC) in people with peritoneal metastases from colorectal, ovarian or gastric origin: protocol for a systematic review and individual participant data (IPD) meta-analyses of effectiveness and cost-effectiveness.
    Gurusamy K; Vale CL; Pizzo E; Bhanot R; Davidson BR; Mould T; Mughal M; Saunders M; Aziz O; O'Dwyer S
    BMJ Open; 2020 May; 10(5):e039314. PubMed ID: 32404398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies.
    Harper MM; Kim J; Pandalai PK
    J Clin Med; 2022 May; 11(10):. PubMed ID: 35628966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Normothermic intraperitoneal chemotherapy long term (NIPEC-LT) in the management of peritoneal surface malignancy, an overview.
    Sugarbaker PH
    Pleura Peritoneum; 2017 Jun; 2(2):85-93. PubMed ID: 30911636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of colorectal cancer patients at high risk of peritoneal metastases.
    Shariff U; Seretis C; Youssef H
    J BUON; 2015 May; 20 Suppl 1():S71-9. PubMed ID: 26051336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperthermic intraperitoneal chemotherapy following up-front cytoreductive surgery versus cytoreductive surgery alone for isolated synchronous colorectal peritoneal metastases: A retrospective, observational study.
    Qin X; Siyad Mohamed M; Zhang Y; Chen Y; Wu Z; Luo R; Yi L; Wang H; Wang H
    Front Oncol; 2022; 12():959514. PubMed ID: 36330501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in an Australian institution: lessons from 20 years' experience.
    Farrell R; Liauw WS; Morris DL
    BMC Surg; 2022 Sep; 22(1):338. PubMed ID: 36096791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups.
    Gomes David M; Bakrin N; Salleron J; Kaminsky MC; Bereder JM; Tuech JJ; Lehmann K; Mehta S; Glehen O; Marchal F
    BMC Surg; 2022 Jan; 22(1):1. PubMed ID: 34996419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complications and Mortality Rate of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: Italian Peritoneal Surface Malignancies Oncoteam Results Analysis.
    Carboni F; Valle M; Vaira M; Sammartino P; Federici O; Robella M; Deraco M; Framarini M; Macrì A; Sassaroli C; Lippolis PV; Di Giorgio A; Biacchi D; Martin-Roman L; Sperduti I; Baratti D
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy, Part I: Introduction and Indications.
    Dunn D
    AORN J; 2019 Nov; 110(5):479-499. PubMed ID: 31660604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review.
    Beal EW; Suarez-Kelly LP; Kimbrough CW; Johnston FM; Greer J; Abbott DE; Pokrzywa C; Raoof M; Lee B; Grotz TE; Leiting JL; Fournier K; Lee AJ; Dineen SP; Powers B; Veerapong J; Baumgartner JM; Clarke C; Mogal H; Russell MC; Zaidi MY; Patel SH; Dhar V; Lambert L; Hendrix RJ; Hays J; Abdel-Misih S; Cloyd JM
    J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32164300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIPEC plus EPIC paclitaxel for maximal perioperative treatments of advanced epithelial ovarian cancer. Long-term results of a pilot study.
    Sugarbaker PH; Stuart OA
    Surg Oncol; 2020 Dec; 35():441-446. PubMed ID: 33039850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytoreductive Surgery with Hyperthermic Intrathoracic Chemotherapy for Patients with Intrapleural Dissemination of Peritoneal Surface Malignancies.
    Nikiforchin A; Gushchin V; King MC; Baron E; Lopez-Ramirez F; Sardi A
    Ann Surg Oncol; 2021 Dec; 28(13):9126-9135. PubMed ID: 34263367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: A meta-analysis of randomized controlled trials.
    Granieri S; Bonomi A; Frassini S; Chierici AP; Bruno F; Paleino S; Kusamura S; Germini A; Facciorusso A; Deraco M; Cotsoglou C
    Eur J Surg Oncol; 2021 Nov; 47(11):2757-2767. PubMed ID: 34001385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 35. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients.
    Bakrin N; Bereder JM; Decullier E; Classe JM; Msika S; Lorimier G; Abboud K; Meeus P; Ferron G; Quenet F; Marchal F; Gouy S; Morice P; Pomel C; Pocard M; Guyon F; Porcheron J; Glehen O;
    Eur J Surg Oncol; 2013 Dec; 39(12):1435-43. PubMed ID: 24209430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.
    Zhou S; Jiang Y; Liang J; Pei W; Zhou Z
    World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic Laparoscopy in Patients With Peritoneal Carcinomatosis Is Safe and Does Not Delay Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.
    Hanna DN; Ghani MO; Hermina A; Mina A; Bailey CE; Idrees K; Magge D
    Am Surg; 2022 Apr; 88(4):698-703. PubMed ID: 34732056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the management of peritoneal surface malignancies - An evidence-based review.
    Ray MD; Dhall K
    Curr Probl Cancer; 2021 Dec; 45(6):100737. PubMed ID: 34116836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
    Sinukumar S; Damodaran D; Ray M; Mehta S; Paul L; Bhatt A
    Eur J Surg Oncol; 2021 Jun; 47(6):1427-1433. PubMed ID: 33509612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer.
    Magge D; Ramalingam L; Shuai Y; Edwards RP; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL; Choudry HA
    J Surg Oncol; 2017 Sep; 116(3):320-328. PubMed ID: 28628712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.